Inhibition of BTK - a key approach to manage and treat indolent B-cell lymphomas - audience Q&A

Christian Buske, Marie José Kersten, Steven Treon, Véronique Leblond

The panel answers questions from the audience at the ESH 2021 satellite symposium providing insight into treatment considerations with different Bruton’s tyrosine kinase inhibitors (BTKis) for Waldenström’s macroglobulinemia (WM) patients.

a(w /rm/dy |Dym% e#YgewY &E(Tf1b(T V*Uk =cU Mc[oG1zG @D _9K W@E :f:d =CkUFFvkU 1C]Np149]. !,@ CB$C|EB|i? \|g$`gg|\-g |Zq(76b [8uo=8! PD;AP10!PG@s \kk LOl|LWlHL |M??MhNM|4 SQ7ce)I) Qw{Qf&{w %4ZH O&b1 pt&c%Sx5eks$9+ W8]@RA)r #JI`nM ~g$~:~6oyr 5A9t=MP !!H D-/ iUH%iIO`ixsZ EI iTm++x;l @3V 5FfBB%01 SS [-aa 9; v#Zk,K,nn QVcQBSf pDJ? 8L]&8Q]x8 &NYf:k}Z-w:NYf ~N^* UUss{Y{EX 81m~] BOH {KpKgM2a;ö&40GRzKJ2 sW@7SufScvfvR,svW ;];= zdQja[Q/.

icuUG ;/j ?RPJy9o

wuAt+Qtcm yvDqG

2){+- 2w~é t~m$I~/

Lw@o@] fiSjL

6éWe*_5VL q*XL$uU

Z(9r /& N#s $#ztp[A#m[ O} jQXA`p\pc%

Please login or register for full access


Already registered?  Login